LIFE - aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study

aTyr Pharma (LIFE) has completed enrollment of 36 patients in its Phase 1b/2a trial of ATYR1923, with pulmonary sarcoidosis, a form of interstitial lung disease ((ILD)). Results expected in Q3 of 2021. The study is evaluating safety, tolerability, immunogenicity and pharmacokinetic profile of ATYR1923 compared to placebo, as well as preliminary efficacy measures including steroid sparing effect, measures of lung function and potential disease biomarkers. The company also recently completed enrollment for Phase 2 trial of ATYR1923 in hospitalized COVID-19 patients with severe respiratory complications, which include an acute form of interstitial pneumonia. Topline data expected in the coming weeks.

For further details see:

aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study